SG11202113253SA - Engineered casx systems - Google Patents
Engineered casx systemsInfo
- Publication number
- SG11202113253SA SG11202113253SA SG11202113253SA SG11202113253SA SG11202113253SA SG 11202113253S A SG11202113253S A SG 11202113253SA SG 11202113253S A SG11202113253S A SG 11202113253SA SG 11202113253S A SG11202113253S A SG 11202113253SA SG 11202113253S A SG11202113253S A SG 11202113253SA
- Authority
- SG
- Singapore
- Prior art keywords
- engineered
- casx
- systems
- casx systems
- engineered casx
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962858750P | 2019-06-07 | 2019-06-07 | |
US201962944892P | 2019-12-06 | 2019-12-06 | |
US202063030838P | 2020-05-27 | 2020-05-27 | |
PCT/US2020/036505 WO2020247882A1 (en) | 2019-06-07 | 2020-06-05 | Engineered casx systems |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202113253SA true SG11202113253SA (en) | 2021-12-30 |
Family
ID=71899867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202113253SA SG11202113253SA (en) | 2019-06-07 | 2020-06-05 | Engineered casx systems |
Country Status (16)
Country | Link |
---|---|
US (3) | US11560555B2 (en) |
EP (1) | EP3980533A1 (en) |
JP (1) | JP2022534809A (en) |
KR (1) | KR20220032050A (en) |
CN (1) | CN114375334A (en) |
AU (1) | AU2020289591A1 (en) |
BR (1) | BR112021024288A2 (en) |
CA (1) | CA3142883A1 (en) |
CL (1) | CL2021003233A1 (en) |
GB (1) | GB2600274A (en) |
IL (1) | IL288738A (en) |
MX (1) | MX2021015058A (en) |
PE (1) | PE20220256A1 (en) |
SG (1) | SG11202113253SA (en) |
TW (1) | TW202113074A (en) |
WO (1) | WO2020247882A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210309981A1 (en) * | 2018-08-22 | 2021-10-07 | Junjie Liu | Variant type v crispr/cas effector polypeptides and methods of use thereof |
CN114375334A (en) | 2019-06-07 | 2022-04-19 | 斯克里贝治疗公司 | Engineered CasX system |
WO2021050593A1 (en) | 2019-09-09 | 2021-03-18 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of sod1 |
WO2021113763A1 (en) | 2019-12-06 | 2021-06-10 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of rhodopsin |
AU2021206270A1 (en) * | 2020-01-10 | 2022-07-21 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of PCSK9 |
KR20230002401A (en) | 2020-03-18 | 2023-01-05 | 스크라이브 테라퓨틱스 인크. | Compositions and methods for targeting C9orf72 |
MX2023006566A (en) | 2020-12-03 | 2023-08-07 | Scribe Therapeutics Inc | Engineered class 2 type v crispr systems. |
US20240100185A1 (en) | 2020-12-03 | 2024-03-28 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of ptbp1 |
US20240033377A1 (en) | 2020-12-09 | 2024-02-01 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
JP2024509264A (en) * | 2021-03-09 | 2024-02-29 | アーバー バイオテクノロジーズ, インコーポレイテッド | Compositions containing variant polypeptides and uses thereof |
BR112023024985A2 (en) | 2021-06-01 | 2024-02-20 | Arbor Biotechnologies Inc | GENE EDITING SYSTEMS COMPRISING A CRISPR NUCLEASE AND USES THEREOF |
WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
AU2022349627A1 (en) * | 2021-09-21 | 2024-03-21 | Scribe Therapeutics Inc. | Engineered casx repressor systems |
IL311611A (en) | 2021-09-23 | 2024-05-01 | Scribe Therapeutics Inc | Self-inactivating vectors for gene editing |
CN116497002A (en) * | 2022-01-19 | 2023-07-28 | 中国科学院动物研究所 | Engineered CasX nucleases, effector proteins and uses thereof |
WO2023235818A2 (en) | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
WO2023235888A2 (en) | 2022-06-03 | 2023-12-07 | Scribe Therapeutics Inc. | COMPOSITIONS AND METHODS FOR CpG DEPLETION |
TW202405175A (en) | 2022-06-07 | 2024-02-01 | 美商斯奎柏治療公司 | Compositions and methods for the targeting of pcsk9 |
WO2023240027A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Particle delivery systems |
WO2023240074A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
WO2023240162A1 (en) | 2022-06-08 | 2023-12-14 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
WO2023240157A2 (en) | 2022-06-08 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of dmd |
WO2024081711A2 (en) * | 2022-10-11 | 2024-04-18 | The Broad Institute, Inc. | Reprogramable tnpb polypeptides and use thereof |
CN117296799B (en) * | 2023-11-28 | 2024-02-02 | 四川省医学科学院·四川省人民医院 | Construction method and application of retinal pigment degeneration disease model |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
DK2356270T3 (en) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
WO2010075303A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same |
US9580714B2 (en) | 2010-11-24 | 2017-02-28 | The University Of Western Australia | Peptides for the specific binding of RNA targets |
PT2800811T (en) | 2012-05-25 | 2017-08-17 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
EP3666895A1 (en) | 2015-06-18 | 2020-06-17 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
EP3365441A1 (en) | 2015-10-22 | 2018-08-29 | The Broad Institute Inc. | Type vi-b crispr enzymes and systems |
WO2017083722A1 (en) | 2015-11-11 | 2017-05-18 | Greenberg Kenneth P | Crispr compositions and methods of using the same for gene therapy |
US11118194B2 (en) | 2015-12-18 | 2021-09-14 | The Regents Of The University Of California | Modified site-directed modifying polypeptides and methods of use thereof |
US9896696B2 (en) | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
AU2017280353B2 (en) | 2016-06-24 | 2021-11-11 | Inscripta, Inc. | Methods for generating barcoded combinatorial libraries |
WO2018035250A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
AU2017335890B2 (en) | 2016-09-30 | 2024-05-09 | The Regents Of The University Of California | RNA-guided nucleic acid modifying enzymes and methods of use thereof |
US9982267B2 (en) | 2016-10-12 | 2018-05-29 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
IL267470B2 (en) | 2017-01-10 | 2023-10-01 | F O R E Biotherapeutics Ltd | Methods for in vitro site-directed mutagenesis using gene editing technologies |
SG11201906297QA (en) | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
WO2018195555A1 (en) | 2017-04-21 | 2018-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors |
US11578334B2 (en) | 2017-10-25 | 2023-02-14 | Monsanto Technology Llc | Targeted endonuclease activity of the RNA-guided endonuclease CasX in eukaryotes |
US10253365B1 (en) | 2017-11-22 | 2019-04-09 | The Regents Of The University Of California | Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs |
US20210054370A1 (en) | 2018-02-27 | 2021-02-25 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating angelman syndrome |
US20200224160A1 (en) | 2018-02-27 | 2020-07-16 | Sorrento Therapeutics, Inc. | Process for dna integration using rna-guided endonucleases |
EP3788144A4 (en) | 2018-05-01 | 2022-05-11 | The Children's Medical Center Corporation | Enhanced bcl11a rnp / crispr delivery & editing using a 3xnls-cas9 |
US20210139892A1 (en) | 2018-07-05 | 2021-05-13 | The Regents Of The University Of California | Compositions and methods for delivery of rna to a cell |
US20210284981A1 (en) | 2018-07-24 | 2021-09-16 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
US20210309981A1 (en) | 2018-08-22 | 2021-10-07 | Junjie Liu | Variant type v crispr/cas effector polypeptides and methods of use thereof |
WO2020247883A2 (en) | 2019-06-07 | 2020-12-10 | Scribe Therapeutics Inc. | Deep mutational evolution of biomolecules |
CN114375334A (en) | 2019-06-07 | 2022-04-19 | 斯克里贝治疗公司 | Engineered CasX system |
US20220315914A1 (en) | 2019-07-08 | 2022-10-06 | The Regents Of The University Of California | Variant type v crispr/cas effector polypeptides and methods of use thereof |
CN114340656A (en) | 2019-08-02 | 2022-04-12 | 孟山都技术公司 | Methods and compositions for facilitating targeted genome modification using HUH endonucleases |
WO2021050593A1 (en) | 2019-09-09 | 2021-03-18 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of sod1 |
WO2021084533A1 (en) | 2019-10-28 | 2021-05-06 | Targetgene Biotechnologies Ltd | Pam-reduced and pam-abolished cas derivatives compositions and uses thereof in genetic modulation |
CN115175921A (en) | 2019-12-06 | 2022-10-11 | 斯克里贝治疗公司 | Particle delivery system |
WO2021113769A1 (en) | 2019-12-07 | 2021-06-10 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of htt |
KR20230002401A (en) | 2020-03-18 | 2023-01-05 | 스크라이브 테라퓨틱스 인크. | Compositions and methods for targeting C9orf72 |
MX2023006566A (en) | 2020-12-03 | 2023-08-07 | Scribe Therapeutics Inc | Engineered class 2 type v crispr systems. |
-
2020
- 2020-06-05 CN CN202080056141.9A patent/CN114375334A/en active Pending
- 2020-06-05 JP JP2021572556A patent/JP2022534809A/en active Pending
- 2020-06-05 TW TW109119111A patent/TW202113074A/en unknown
- 2020-06-05 GB GB2200132.5A patent/GB2600274A/en active Pending
- 2020-06-05 PE PE2021002050A patent/PE20220256A1/en unknown
- 2020-06-05 CA CA3142883A patent/CA3142883A1/en active Pending
- 2020-06-05 KR KR1020227000734A patent/KR20220032050A/en unknown
- 2020-06-05 WO PCT/US2020/036505 patent/WO2020247882A1/en unknown
- 2020-06-05 SG SG11202113253SA patent/SG11202113253SA/en unknown
- 2020-06-05 BR BR112021024288A patent/BR112021024288A2/en unknown
- 2020-06-05 AU AU2020289591A patent/AU2020289591A1/en active Pending
- 2020-06-05 EP EP20750444.0A patent/EP3980533A1/en active Pending
- 2020-06-05 MX MX2021015058A patent/MX2021015058A/en unknown
-
2021
- 2021-11-23 US US17/533,997 patent/US11560555B2/en active Active
- 2021-12-03 US US17/542,219 patent/US20220220508A1/en active Pending
- 2021-12-06 IL IL288738A patent/IL288738A/en unknown
- 2021-12-06 CL CL2021003233A patent/CL2021003233A1/en unknown
-
2022
- 2022-11-22 US US18/058,251 patent/US20230124880A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2021003233A1 (en) | 2022-08-12 |
CN114375334A (en) | 2022-04-19 |
EP3980533A1 (en) | 2022-04-13 |
GB2600274A (en) | 2022-04-27 |
KR20220032050A (en) | 2022-03-15 |
TW202113074A (en) | 2021-04-01 |
PE20220256A1 (en) | 2022-02-21 |
JP2022534809A (en) | 2022-08-03 |
MX2021015058A (en) | 2022-04-06 |
CA3142883A1 (en) | 2020-12-10 |
AU2020289591A1 (en) | 2021-12-23 |
US11560555B2 (en) | 2023-01-24 |
BR112021024288A2 (en) | 2022-02-15 |
IL288738A (en) | 2022-02-01 |
US20220220508A1 (en) | 2022-07-14 |
US20230124880A1 (en) | 2023-04-20 |
US20220081681A1 (en) | 2022-03-17 |
WO2020247882A1 (en) | 2020-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202113253SA (en) | Engineered casx systems | |
SG11202100791UA (en) | Cross-blockchain interaction systems | |
IL282092B (en) | Engineered enzymes | |
CA190078S (en) | Case | |
GB2597191B (en) | Product-display system | |
EP3635101A4 (en) | Engineered ligase variants | |
GB201806508D0 (en) | Systems | |
GB201902167D0 (en) | Communications systems | |
IL286570A (en) | System | |
IL279880A (en) | Engineered phosphopentomutase variant enzymes | |
SG11202003030RA (en) | Reactor systems | |
GB202012051D0 (en) | Delivery systems | |
GB202114885D0 (en) | Earphone systems | |
EP3924957C0 (en) | Cloth-tensioning system | |
SG11202112164VA (en) | Novel lower-trolley system | |
SG11202109684RA (en) | Manufacturing system | |
ZA202107297B (en) | Surfactant systems | |
GB201717231D0 (en) | Sheerlock ramp systems limited | |
SG11202110786SA (en) | Cryptographic systems | |
SG11202108273UA (en) | Reactor systems | |
GB201918937D0 (en) | Heating systems | |
GB201912198D0 (en) | Engineered CRISPRa | |
GB201912179D0 (en) | Engineered CRISPRa | |
GB201913941D0 (en) | Aeroslo provision systems | |
GB202017852D0 (en) | Archorage systems |